The aXess clinical study of Xeltis restorative access graft for hemodialysis is proceeding at full speed, announced today Xeltis CEO Eliane Schutte at Biocapital Europe. Over 350 successful dialysis sessions have been completed in patients within six months from trial start, following the recent €15m funding by the European Investment Bank and the successful achievement of grant and equity total of €15m from the European Innovation Council. Xeltis currently has five clinical trials ongoing, covering three different indications.
“Only a year ago, we announced the expansion of our device platform across three different clinical applications, including hemodialysis access, at this conference. Our hemodialysis grafts have now been living and working in patients for months, which is extraordinary, if you think that often times it takes this amount of waiting time to enable hemodialysis via matured fistulas,” said Eliane.
The aXess grafts enable early puncturing, or initiation of the dialysis, shortly after implanting. Over time, they turn into living blood vessels, as their porous micro-structure gets colonized by the patient’s own tissue. Today, patients with kidney failure may wait for months, or in vain, for fistula maturation to access dialysis or they use synthetic grafts that have limited durability and are prone to clotting and infections.[1],[2]
BioCapital Europe is Europe’s premier life sciences investment conference, offering VCs and institutional investors unique and timely access to around 40 exciting biotech, medtech and diagnostics companies from the Benelux and Europe. Biocapital Europe conference is organized by healthcare investment firm LSP.
[1] Lee T et al. Tradeoffs in Vascular Access Selection in Elderly Patients Initiating Hemodialysis with a Catheter. American Journal of Kidney Diseases. Volume 72, Issue 4, October 2018, Pages 509-518
[2] Schwab SJ et al. Vascular access for hemodialysis. Kidney International. 1999 May;55(5):2078-90. doi: 10.1046/j.1523-1755.1999.00409.x. PMID: 10231476.
